Sector News

UK drugmakers back in spotlight as bidders free to return

November 24, 2014
Life sciences
Two of the UK’s biggest health care companies, AstraZeneca and Smith & Nephew, will be pushed into the spotlight again this week as bidding restrictions on their former suitors expire.
 
After a six-month cooling off period, US drugmaker Pfizer will be able to approach AstraZeneca again, while the American orthopaedic company Stryker will also be allowed to return for hip and knee replacement maker Smith & Nephew.
 
Stryker is understood to be still keen but unlikely to return immediately after the takeover deadline ends on Friday. It is expected to return next year.
 
Stryker is under pressure to do a deal as its orthopaedic rivals, Zimmer, Biomet and Johnson & Johnson have already struck their own blockbuster deals.
 
However, sources have called the Pfizer-AstraZeneca situation “dead” and said the US drugmaker is now focused on other opportunities. Pfizer was said to have turned its attentions to rival US drugmaker Actavis, but Actavis bulked up with its $66bn acquisition of Allergan. The Swiss biotech company Actelion has also been on its radar.
 
Meanwhile, AstraZeneca’s share price has risen on the back of a boost in its pipeline, making it unlikely that Pfizer would be able to afford the group, particularly now the tax benefits of a deal have been complicated by new US Treasury rules.
 
Takeover Panel rules require bidders to walk away for six months after a failed bid, but few return. The last occasion was in 2001 when French industrial group Lafarge returned for UK cement maker Blue Circle.
 
By Ashley Armstrong
 

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]